ER-803022 free acid | 287180-60-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: ER-803022 free acid
• 英文别名: [(3R)-1-[(2R)-3-[2-[2-[[(2R)-3-[(3R)-3-dodecanoyloxydecoxy]-2-(tetradecanoylamino)propoxy]-hydroxyphosphoryl]oxyethylcarbamoylamino]ethoxy-hydroxyphosphoryl]oxy-2-(tetradecanoylamino)propoxy]decan-3-yl] dodecanoate
• CAS: 287180-60-3
• 化学式: C₈₃H₁₆₄N₄O₁₇P₂
• 分子量: 1552.2
• InChiKey: RQFCPMLFCUQAEU-RIRPJZCXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  25.6
• 重原子数：
  106
• 可旋转键数：
  86
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  282
• 氢给体数：
  6
• 氢受体数：
  17

文献信息

• Chlamydia antigens
  申请人：GLAXOSMITHKLINE BIOLOGICALS, S.A.

  公开号：US10716842B2

  公开（公告）日：2020-07-21

  The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

  本发明提供了用于治疗、预防和/或诊断衣原体感染的衣原体抗原。特别是，本发明提供了来自沙眼衣原体的抗原 CT733、CTI 53、CT601、CT279、CT443、CT372、CT456、CT381、CT255、CT341、CT716、CT745、CT387、CT812、CT869、CT166、CT175、CT163、CT214、CT721、CT127、CT043、CT823 和/或 CT600，用于治疗、预防或诊断衣原体感染。
• Immunomodulatory compounds and methods of use thereof
  申请人：Hawkins D. Lynn

  公开号：US20070027111A1

  公开（公告）日：2007-02-01

  The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, therapeutic and prophylactic treatment of cancer, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.
• Mutant Forms of Chlamydia HtrA
  申请人：Novartis AG

  公开号：US20150202280A1

  公开（公告）日：2015-07-23

  An immunogenic Chlamydia HtrA protein, which has one or more mutations relative to wild-type Chlamydia HtrA that result in a reduced or eliminated protease activity relative to the protease activity of wild-type Chlamydia HtrA. Preferably, it is the serine protease activity that is reduced or eliminated.
• CHLAMYDIA ANTIGENS
  申请人：Glaxosmithkline Biologicals SA

  公开号：US20160158337A1

  公开（公告）日：2016-06-09

  The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
• US7560584B2
  申请人：——

  公开号：US7560584B2

  公开（公告）日：2009-07-14